ReviewAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2025

Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future.

Taha Mansoor et al.PubMed ↗Publisher ↗

No numbers read from the abstract.